Analysts at Sterling Investment Services today reiterated the Buy rating on medical technology company OxySure Systems. The firm set a 12-month price target of $1.90 on OXYS’ common stock.

This is the third recently issued Buy rating on OXYS with a price target in the range of $1.75 to $2.10.

OxySure focuses on the design, manufacture, and distribution of specialty respiratory and medical solutions. The company pioneered an FDA-approved solution to produce medically pure (USP) oxygen from inert powders for emergency and short duration use. The company owns several issued patents and patents pending on this technology, which makes the provision of emergency oxygen safer, more accessible, and easier to use than traditional oxygen provision systems.

To see the Sterling report in its entirety, visit http://oxysure.com/aed/sterlingoxysure.pdf. For more information on OxySure, visit www.OxySure.com.

Let us hear your thoughts below: